HEMOSTEMIX INC (HEM.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:HEM - CA4236943060 - Common Stock
HEM.CA Key Statistics, Chart & Performance
The current stock price of HEM.CA is 0.075 CAD. In the past month the price decreased by -16.67%. In the past year, price decreased by -6.25%.
HEM.CA Latest News, Press Relases and Analysis
HEM.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 408.24M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 367.23M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 177.97M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 130.12M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.63 | 54.41M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 35.92M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.42M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 32.22M | ||
| MPH.CA | MEDICURE INC | N/A | 13.99M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.16M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 5.92M | ||
| APS.CA | APTOSE BIOSCIENCES INC | N/A | 5.69M |
Related stock screener links
About HEM.CA
Company Profile
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The firm has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). The company holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. The company has completed a Phase II clinical trial for chronic limb-threatening ischemia. The company has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Company Info
HEMOSTEMIX INC
707 7th Ave. SW, Suite 1150
Calgary ALBERTA T2P 3H6 CA
CEO: Thomas Smeenk
Employees: 9
Phone: 19055804170
HEMOSTEMIX INC / HEM.CA FAQ
What does HEMOSTEMIX INC do?
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The firm has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). The company holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. The company has completed a Phase II clinical trial for chronic limb-threatening ischemia. The company has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Can you provide the latest stock price for HEMOSTEMIX INC?
The current stock price of HEM.CA is 0.075 CAD. The price decreased by -11.76% in the last trading session.
Does HEMOSTEMIX INC pay dividends?
HEM.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of HEM stock?
HEM.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is HEMOSTEMIX INC (HEM.CA) stock traded?
HEM.CA stock is listed on the TSX Venture Exchange exchange.
Can you provide the number of employees for HEMOSTEMIX INC?
HEMOSTEMIX INC (HEM.CA) currently has 9 employees.
What is HEMOSTEMIX INC worth?
HEMOSTEMIX INC (HEM.CA) has a market capitalization of 14.14M CAD. This makes HEM.CA a Nano Cap stock.
HEM.CA Technical Analysis
HEM.CA Financial Highlights
Over the last trailing twelve months HEM.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -41.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -346.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |